<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369915</url>
  </required_header>
  <id_info>
    <org_study_id>060234</org_study_id>
    <secondary_id>06-M-0234</secondary_id>
    <nct_id>NCT00369915</nct_id>
  </id_info>
  <brief_title>The Antidepressant Efficacy of the Anticholinergic Scopolamine</brief_title>
  <official_title>The Antidepressant Efficacy of the Anticholinergic Scopolamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      A previous study showed that the intravenous administration of scopolamine produces
      antidepressant effects. This study is designed to determine if other routes of administration
      of scopolamine produce antidepressant effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the availability of a wide range of antidepressant drugs, clinical trials indicate
      that 30% to 40% of patients with major depression fail to respond to first-line
      antidepressant treatment, despite adequate dosage, duration, and compliance. Moreover, in
      those patients who do experience symptomatic relief following conventional anti-depressant
      treatment, clinical improvement is not evident for 3-4 weeks. Thus, there is a clear need to
      develop novel and improved therapeutics for unipolar and bipolar depression.

      The cholinergic system is one of the neurotransmitter systems implicated in the
      pathophysiology of mood disorders. Evidence suggests that during major depressive episodes,
      the cholinergic system is hypersensitive to acetylcholine. Agents that enhance muscarinic
      cholinergic receptor function increase depressive symptoms in depressed subjects, and can
      produce symptoms of depression in healthy individuals. The preclinical literature more
      specifically implicates the muscarinic receptors and indicates that the use of muscarinic
      antagonists, in the context of animal models of depression, results in improvement in the
      behavioral analogs of depression.

      Preliminary results obtained under protocol 3-M-0108 provide strong evidence for the
      potential effectiveness of the anticholinergic scopolamine in rapidly producing clinically
      significant antidepressant effects. We observed large reductions in Montgomery-Asberg
      Depression Rating Scale (MADRS) scores that occurred over hours/days following i.v. infusion
      of scopolamine, which stood in marked contrast to the 3-4 week period generally required for
      conventional therapies. Moreover, these improvements were observed in subjects who had been
      nonresponsive or incompletely responsive to conventional antidepressant therapies,
      highlighting the potential for this treatment to benefit a larger percentage of individuals
      with depression. The goal of this research project is to perform a clinical trial to evaluate
      the efficacy of the muscarinic cholinergic receptor antagonist scopolamine administered via
      transdermal patch on clinical symptoms of depression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Depression Severity</measure>
    <time_frame>Outcome measures obtained at each of 12 sessions</time_frame>
    <description>The Montgomery-Asberg Depression Rating Scale (MADRS) has a range of scores from 0 to 60 where the highest values indicate the most depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale</measure>
    <time_frame>Each of 12 sessions.</time_frame>
    <description>The Hamilton Anxiety Rating Scale (HARS) has a range of scores from 0 to 56 where the highest values indicate the most anxiety.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Unipolar Depression</condition>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Plac/Scop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo then scopolamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scop/Plac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scopolamine then placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <arm_group_label>Scop/Plac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <arm_group_label>Plac/Scop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Two groups of subjects will be recruited for studies under this protocol: unipolar
        depressives and bipolar depressives. Subjects with unipolar or bipolar depression appear to
        exhibit abnormal cholinergic function during the depressed phase, and no differences are
        hypothesized to exist between MDD and BD depressives herein. However, while BD subjects are
        more difficult to recruit, the evidence for cholinergic abnormalities has been particularly
        compelling for BD. Moreover, observations from our pilot study suggest that scopolamine
        will improve symptoms in both MDD and BD, a particularly persuasive observation given BD
        notoriously has been difficult to treat. Thus, the magnitude of this serious clinical
        problem justifies the inclusion of BD subjects. Therefore both groups will be recruited.
        However, BD Type I subjects will be included only if they are currently stable on lithium
        or valproate to reduce the risks associated with possible precipitation of mania.

        The presence of inclusion and exclusion criteria will be established using both an
        unstructured clinical interview with a psychiatrist and the Structured Clinical Interview
        for DSM-IV (SCID). Family history of mental illness will be obtained from the subject using
        the Family Interview of Genetic Studies. We will recruit 24 subjects per group.

        DEPRESSED SAMPLES: Subjects (ages 18-55) currently suffering from a major depressive
        episode falling into one of the following subgroups:

          1. . MAJOR DEPRESSIVE DISORDER (MDD): Subjects will be selected with primary MDD and are
             currently depressed as defined by DSM-IV criteria for recurrent MDD and current MADRS
             score in the moderately-to-severely depressed range (greater than or equal to 20). The
             duration of the index episode is greater than or equal to four weeks.

          2. . BIPOLAR DISORDER TYPE II (BD): Subjects will be selected who meet DSM-IV criteria
             for bipolar disorder Type I or II and are currently depressed, with MADRS score in the
             moderately-to-severely depressed range (greater than or equal to 20). The duration of
             the index episode is greater than or equal to four weeks.

        EXCLUSION CRITERIA:

        Subjects will be recruited who are drug-naive or who have not received psychotropic drugs
        for at least 3 weeks (8 weeks for fluoxetine) prior to screening. Subjects also will be
        excluded if they have: a) serious suicidal ideation or behavior, or current delusions or
        hallucinations, b) inability to provide informed consent, c) serious, unstable illnesses
        including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including
        ischemic heart disease, endocrinologic, neurologic, immunologic, or hematologic disease, d)
        a history of drug or alcohol abuse within 6 months or alcohol or drug dependence in the
        last five years (DSM IV criteria), e) not using a medically accepted means of contraception
        and are a woman of childbearing potential, f) current pregnancy (documented by pregnancy
        testing prior to each brain scan to avoid exposing a fetus to radiation or to a research
        MRI scan that is not medically necessary), g) current breast feeding, h) history of
        ulcerative colitis or toxic megacolon, i) vision and/or hearing problems severe enough to
        interfere with testing, j) electrocardiographic evidence of ischemia, arrhythmia,
        conduction defect, or myocardial infarction, k) current blood pressure of greater than 160
        mm Hg or less than 90 mm Hg systolic, or greater than 90 mm Hg diastolic, l) clinically
        significant cerebrovascular or cardiovascular disease, hypertension, congestive heart
        disease, angina pectoris, clinic evidence of cerebrovascular disease, gross neurological
        impairment, hyperthyroidism, known hypersensitivity or idiosyncracy to anticholinergic
        agents (e.g. skin rashes), glaucoma, renal or hepatic impairment, m) current nicotine use
        or nicotine dependence within last six months (due to the effects of nicotine on the
        cholinergic system) n) narrow angle glaucoma (due to the possibility of exacerbation of
        this condition by scopolamine) o) age greater than 55 years (to reduce the biological
        heterogeneity encompassed by the MDD and BD criteria, since subjects with a late age-at
        onset for depression have a far greater likelihood of having MRI correlates of
        cerebrovascular disease than age-matched, healthy controls or age-matched, early-onset
        depressives), p) exposure within two weeks to medications likely to affect mood or
        cognition or likely to interact with scopolamine (e.g. narcotics or anti-cholinergic
        agents)- as verified by history and urine drug screen, q) HIV positive status, r) history
        of gastric or intestinal obstructions, s) history of urinary retention or bladder
        obstruction. During the course of this study, participants will be unable to take some
        medications, including antidepressant or antianxiety agents, sleep aids, diphenhydramine
        (e.g. Benedryl) or cough/cold preparations that contain diphenhydramine or antihistamines.
        A detailed list of allowed and not allowed medications is provided in Appendix B in the
        protocol.

        We are not excluding comorbid anxiety disorders. Exclusion of patients with comorbid
        anxiety disorders would affect the generalizability of our findings since a substantial
        percentage of patients with major depression have these comorbid diagnoses. Instead, we
        will exclude patients with this comorbid diagnosis only if it is believed to be of clinical
        significance. Allowing participation by patients with histories of comorbid anxiety
        disorders broadens the inclusion criteria to more closely approximate patients seen in real
        world settings.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maura L Furey, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Janowsky DS, el-Yousef MK, Davis JM. Acetylcholine and depression. Psychosom Med. 1974 May-Jun;36(3):248-57.</citation>
    <PMID>4829619</PMID>
  </reference>
  <reference>
    <citation>Janowsky DS, el-Yousef MK, Davis JM, Hubbard B, Sekerke HJ. Cholinergic reversal of manic symptoms. Lancet. 1972 Jun 3;1(7762):1236-7.</citation>
    <PMID>4113219</PMID>
  </reference>
  <reference>
    <citation>Janowsky EC, Risch C, Janowsky DS. Effects of anesthesia on patients taking psychotropic drugs. J Clin Psychopharmacol. 1981 Jan;1(1):14-20. Review.</citation>
    <PMID>6117578</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2006</study_first_submitted>
  <study_first_submitted_qc>August 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2006</study_first_posted>
  <results_first_submitted>April 11, 2014</results_first_submitted>
  <results_first_submitted_qc>March 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2016</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholinergic</keyword>
  <keyword>Unipolar</keyword>
  <keyword>Bipolar</keyword>
  <keyword>Depression</keyword>
  <keyword>Muscarinic</keyword>
  <keyword>Scopolamine</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>MDD</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>BP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Cholinergic Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Plac/Scop</title>
          <description>6 administrations of placebo patch at 4 to 5 day intervals; followed by 6 administrations of scopolamine patch at 4 to 5 day intervals</description>
        </group>
        <group group_id="P2">
          <title>Scop/Plac</title>
          <description>6 administrations of scopolamine patch at 4 to 5 day intervals; followed by 6 administrations of placebo patch at 4 to 5 day intervals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>expected side effects</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>W/drawl by investigators</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Plac/Scop</title>
          <description>6 administrations of placebo patch at 4 to 5 day intervals; followed by 6 administrations of scopolamine patch at 4 to 5 day intervals</description>
        </group>
        <group group_id="B2">
          <title>Scop/Plac</title>
          <description>6 administrations of scopolamine patch at 4 to 5 day intervals; followed by 6 administrations of placebo patch at 4 to 5 day intervals</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="6.6"/>
                    <measurement group_id="B2" value="33" spread="10.4"/>
                    <measurement group_id="B3" value="31.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Depression Severity</title>
        <description>The Montgomery-Asberg Depression Rating Scale (MADRS) has a range of scores from 0 to 60 where the highest values indicate the most depression.</description>
        <time_frame>Outcome measures obtained at each of 12 sessions</time_frame>
        <population>Only participants who completed the trial were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Plac/Scop</title>
            <description>6 administrations of placebo patch at 4 to 5 day intervals; followed by 6 administrations of scopolamine patch at 4 to 5 day intervals</description>
          </group>
          <group group_id="O2">
            <title>Scop/Plac</title>
            <description>6 administrations of scopolamine patch at 4 to 5 day intervals; followed by 6 administrations of placebo patch at 4 to 5 day intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression Severity</title>
          <description>The Montgomery-Asberg Depression Rating Scale (MADRS) has a range of scores from 0 to 60 where the highest values indicate the most depression.</description>
          <population>Only participants who completed the trial were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Block 1 - Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="2.5"/>
                    <measurement group_id="O2" value="30.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="8.2"/>
                    <measurement group_id="O2" value="29.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="3.7"/>
                    <measurement group_id="O2" value="31.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="6.6"/>
                    <measurement group_id="O2" value="27.0" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="7.4"/>
                    <measurement group_id="O2" value="27.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="4.5"/>
                    <measurement group_id="O2" value="28.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="3.7"/>
                    <measurement group_id="O2" value="27.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="3.8"/>
                    <measurement group_id="O2" value="23.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="8.3"/>
                    <measurement group_id="O2" value="20.0" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="9.1"/>
                    <measurement group_id="O2" value="17.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="7.9"/>
                    <measurement group_id="O2" value="16.8" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="8.8"/>
                    <measurement group_id="O2" value="20.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Anxiety Rating Scale</title>
        <description>The Hamilton Anxiety Rating Scale (HARS) has a range of scores from 0 to 56 where the highest values indicate the most anxiety.</description>
        <time_frame>Each of 12 sessions.</time_frame>
        <population>Only study completers were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Plac/Scop</title>
            <description>6 administrations of placebo patch at 4 to 5 day intervals; followed by 6 administrations of scopolamine patch at 4 to 5 day intervals</description>
          </group>
          <group group_id="O2">
            <title>Scop/Plac</title>
            <description>6 administrations of scopolamine patch at 4 to 5 day intervals; followed by 6 administrations of placebo patch at 4 to 5 day intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Anxiety Rating Scale</title>
          <description>The Hamilton Anxiety Rating Scale (HARS) has a range of scores from 0 to 56 where the highest values indicate the most anxiety.</description>
          <population>Only study completers were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Block 1 - Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="6.2"/>
                    <measurement group_id="O2" value="20.3" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="6.2"/>
                    <measurement group_id="O2" value="14.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="8.4"/>
                    <measurement group_id="O2" value="14.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="6.5"/>
                    <measurement group_id="O2" value="13.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="5.0"/>
                    <measurement group_id="O2" value="12.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 1 - Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="7.1"/>
                    <measurement group_id="O2" value="11.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="2.2"/>
                    <measurement group_id="O2" value="13.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="3.8"/>
                    <measurement group_id="O2" value="12.0" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="4.0"/>
                    <measurement group_id="O2" value="13.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="2.7"/>
                    <measurement group_id="O2" value="14.3" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="2.1"/>
                    <measurement group_id="O2" value="10.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Block 2 - Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="3.2"/>
                    <measurement group_id="O2" value="11.8" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Plac/Scop</title>
          <description>6 administrations of placebo patch at 4 to 5 day intervals; followed by 6 administrations of scopolamine patch at 4 to 5 day intervals</description>
        </group>
        <group group_id="E2">
          <title>Scop/Plac</title>
          <description>6 administrations of scopolamine patch at 4 to 5 day intervals; followed by 6 administrations of placebo patch at 4 to 5 day intervals</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mild confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maura Furey, PhD</name_or_title>
      <organization>NIMH/NIH</organization>
      <phone>301-594-7773</phone>
      <email>mfurey@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

